Qinshu Lian

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Nicholas C. Turner, Rebecca Dent, Joyce O’Shaughnessy et al. · Breast Cancer Research and Treatment · 2021 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)

Adam C. Yopp, M. Kudo, Mingkai Chen et al. · Annals of Oncology · 2024 · 85 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks

Heather Guthrie, Lawrence S. Honig, Helen Lin et al. · Journal of Alzheimer s Disease · 2020 · 66 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Prescription opioids are associated with higher mortality in patients diagnosed with sepsis: A retrospective cohort study using electronic health records

Rui Zhang, Jingjing Meng, Qinshu Lian et al. · PLoS ONE · 2018 · 64 citations · Full text

Nursing, Health Informatics, Pharmacotherapy +16